Objectives: The present study was undertaken to determine the effects of free ionized calcium influenced by either the anticoagulant used (citrate vs. heparin) or directly varying the calcium levels after treatment of blood with citrate on the antiplatelet efficacy of two 11 classes of GPIIb / IIIa antagonists. Methods: The platelet effects of changes in plasma [Ca ] with the different GPIIb / IIIa antagonists 125 were determined using light transmittance aggregometry, direct binding kinetics, and I-fibrinogen binding to activated human platelets. Results: A significantly higher IC50s was shown with heparin (free ionized calcium51.1 mM) as compared to that with citrate (free ionized calcium50.12 mM) with class II GPIIb / IIIa antagonists (P,0.01) such as Orbofiban, and Integrilin. In contrast, class I GPIIb / IIIa antagonists such as Roxifiban and Abciximab showed no significant changes in their IC50s in either citrate or heparin. Similar data were shown with other non-calcium chelating anticoagulant such as PPACK as compared to that with heparin. Additionally, similar (P,0.01) in its platelet binding kinetics and antiplatelet efficacy in response to changes in Ca concentrations. Conclusions: These data suggest the impact of the method of blood collection or changes in plasma calcium levels on the antiplatelet efficacy for class II but not class I GPIIb / IIIa antagonists depending on their platelet binding kinetics.
Introduction
angina and percutaneous transluminal coronary angioplasty [8, 9] . Such therapy, however, may be associated with a Platelet-fibrinogen interaction is a key step in the risk of hemorrhagic complications. There is considerable pathogenesis of coronary artery thrombosis [1] [2] [3] [4] . The person-to-person variability in the number of GPIIb / IIIa clinical benefit of aspirin and the more dramatic antithromreceptors and its ligand binding function; in patients with botic effect of intravenous antagonists of the platelet coronary artery disease enhanced platelet GPIIb / IIIa resurface GPIIb / IIIa receptor underscore the importance of ceptor expression may be a marker for increased thromplatelet involvement in acute coronary ischemia [5] [6] [7] . botic risk. Furthermore, variable inhibition levels of Platelet GPIIb / IIIa blockade with c7E3 (ReoPro) reduces GPIIb / IIIa function may occur after administration of the myocardial infarction and death associated with unstable various GPIIb / IIIa antagonists and more so with the oral form of GPIIb / IIIa antagonists. Light transmittance platelet aggregometry of cPRP obtained from citrated This assay was used to determine a compound's saturwhich lower free ionized plasma calcium levels, vs. able binding to platelets using PRP. Either citrated whole heparinized blood, which do not affect free ionized plasma blood (5 ml draw, Vacutainer tubes containing 3.2% calcium concentrations, for various GPIIb / IIIa antagonists sodium citrate) or heparinized whole blood (5 ml draw, having different platelet GPIIb / IIIa binding kinetics.
Vacutainer tubes containing IU / ml heparin) was collected Those GPIIb / IIIa antagonists can be classified based on from healthy, aspirin free, human subjects. Blood was their platelet binding kinetics into two classes. Class I centrifuged for 10 min at 1503g at 228C using Sorvall include GPIIb / IIIa antagonists with relatively high and RT6000 tabletop Centrifuge (DuPont, Wilmington, DE). comparable affinity for both resting and activated platelets PRP was removed, pooled, and platelets were counted and slow platelet dissociation rates. In contrast, class II using a Coulter T540 Hematology Analyzer. Forty microli- 3 3 GPIIb / IIIa antagonists include compounds with relatively ters of H-active form of Roxifiban (77.5 ci / mMol), H- to stand for 60 min, shaken, and counted using a liquid IIIa antagonists were added at different concentrations for scintillation counter. Equilibrium and specific binding 8 min prior to the addition of ADP or TRAP at 10 mM. affinity for the different radiolabeled GPIIb / IIIa antagoResults were expressed as mean IC 6 SEM (mM).
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nists to activated and resting human platelets was calcu-125 lated using Scatchard plot. Non-specific binding (about 2.4. Platelet I-fibrinogen binding assay 5-10% of total binding) of radiolabel GPIIb / IIIa antagonists were determined in the presence of 10 mM EDTA.
Human PRP was applied to a sepharose column to prepare gel filtered platelets (GFP) as previously described 8 
Dissociation rates
[11]. Aliquots of GFP (2310 platelets / ml) along with 1 Citrated whole blood (5 ml draw in Vacutainer tubes, mM calcium chloride with or without the test agent were 125 3.2% sodium citrate) was collected from healthy, aspirinadded to removable 96-well plates. I-fibrinogen (26.5 free, human subjects. Blood samples were divided to be mCi / mg) was added for 10 min, and the h-GFP was used as whole blood or to be centrifuged for 10 min activated by addition of ADP at 10 mM for another 10 min.
125
(1503g), the resulting PRP removed, and platelet counts The I-fibrinogen bound to the activated platelet was determined to normalize the radiolabeled platelets. Desigseparated from the free form by centrifugation, and then nated individual tubes of whole blood were treated for 60 counted on a gamma counter. Non-specific binding (due to 3 125 min, with 0.04 mM of H-active form of Roxifiban. entrapment of I-fibrinogen) either in the presence or Following this 60-min incubation period, the tubes were absence of the inhibitors was shown (in the absence of 3 125 centrifuged for 10 min (1503g). The resulting Hagonist) to be in the range of 4-6% of total I-fibrinogen radioligand / PRP was carefully removed and centrifuged binding to agonist-activated platelets. (Fig. 1A) . In contrast, the platelet binding affinity of antagonists from class II such as Orbofiban demonstrated calcium sensitivity in its binding to either resting or activated human platelets (Fig.  1B) .
Antiplatelet efficacy

Platelet aggregation inhibitory efficacy in citrate vs. heparin
The effects of collecting blood in citrate vs. heparin on the antiplatelet efficacy of 10 different GPIIb / IIIa antagonists (Class I titrators) with high affinity to resting and activated platelets and relatively slow dissociation rates were examined. The same was performed for 22 different GPIIb / IIIa antagonists (Class II non-titrators) with relatively low affinity to resting platelets and faster platelet hPRP. An excellent correlation (r 50.88-0.87) in the antiplatelet efficacy with a slope of 1.2 reflecting a lack of IC50 differences in cPRP vs. hPRP for Class I GPIIb / IIIa antagonists. In contrast, a significant shift in IC50s (slope51.9, P,0.01) was demonstrated with Class II GPIIb / IIIa antagonists when switching from citrate to heparin. Class I GPIIb / IIIa antagonists represent compounds having high affinity for activated and resting platelets along with a relatively slow platelet dissociation rates vs. Class II GPIIb / IIIa antagonists which represent compounds with relatively low affinity for resting platelets and faster platelet dissociation rates. (Figs. 4 and 5) . The inhibitory efficacy of Roxifiban was not affected (Fig. 4A) . In contrast, the inhibitory efficacy of either Integrilin (Fig.  4B) or Orbofiban (Fig. 4C ) was significantly (P,0.01) affected by the change from a lower to normal plasma
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[Ca ] levels of about 0.1 to 1.0 mM. platelet aggregation studies, sodium citrate has been the conventional anticoagulant for the collection of whole blood. Unfortunately, the chelation of calcium from PRP by the citrate may result in weakening the GPIIb / IIIa complex, which is a calcium dependent association of the GPIIb and the IIIa subunits. Under such conditions, ex vivo platelet aggregation measurements might result in an artificially higher level of inhibition than what can be achieved in vivo. Intracellular calcium influences the II) with Integrilin revealed a significant effect of plasma calcium levels on its antiplatelet efficacy [19, 20] . and LeFradafiban demonstrated oral antiplatelet activity in Preclinical and early clinical evaluation of GPIIb / IIIa man upon their administration 2-3 times per day as antagonists relies very much on ex vivo platelet aggregadetermined in cPRP using light transmittance agtion inhibition assays for dose-findings. For ex vivo gregometry [23] [24] [25] [26] [27] . The active form of Roxifiban have distinct platelet GPIIb / IIIa binding characteristics along hirudin in order to study the true antiplatelet efficacy of with a potent in vitro antiplatelet efficacy regardless of the GPIIb / IIIa antagonists from class II. Additionally, a whole ]] agonist or the anticoagulant used for blood collection blood platelet functional assay using the above conditions (citrate vs. heparin) [28, 29] .
should allow for a more relevant bedside platelet moniClass I GPIIb / IIIa antagonists such as Roxifiban equilitoring. brate and titrate to greater extent with human platelets (i.e. This data suggest a major differences between different its platelet / plasma distribution is |10 / 1). Hence its antiplatelet GPIIb-IIIa antagonists which might have major platelet efficacy is not totally dependent on plasma levels.
impacts on their clinical efficacy in different thromboemIn contrast, class II GPIIb / IIIa antagonists exist in equilibbolic disorders. rium between platelet and plasma compartments (i.e. its platelet / plasma ratio of distribution is |1 / 1) and its antiplatelet efficacy depend on plasma levels [30] .
